Related Experiment Video
Updated: Aug 27, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
Bao Tran Vuong1, Chloé M Delépine2, Jacqueline M Ratter-Rieck3
1INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France; Department of Endocrinology and Diabetology, Simone Veil Hospital, Eaubonne, France.
Abstract:
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications do not capture its clinico-biological complexity or support precision-based care. We developed an endotyping strategy based on routine blood immune cell counts across more than 1,500 individuals with newly diagnosed T2D from three European cohorts. Unsupervised clustering identified four reproducible immune endotypes: severe inflammatory diabetes (SIND), mild inflammatory diabetes (MIND), lymphocyte-rich diabetes (LYRD), and lymphocyte-deficient diabetes (LYDD). Endotypes were stable, robust to de novo clustering, and independent of age, sex, BMI, and HbA1c. SIND and LYDD were associated with increased cardiovascular, renal, and mortality risk across cohorts. Immune endotyping improved cardiovascular risk prediction beyond SCORE2-Diabetes. Multi-omic profiling revealed immunopathological states, with high-risk endotypes characterized by monocyte-driven inflammation and dysregulated lymphocyte programs. The inflammatory profile of SIND was attenuated by IL-1β antagonism and bariatric surgery. These findings establish immune endotyping as a scalable framework for immunometabolic risk stratification in T2D.
Related Concept Videos
Type II Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis